Oslo, 22 April 2025 - Reference is made to the notice of the Annual General Meeting in Lytix Biopharma AS (the "Company") which will be held on Tuesday 29 April 2025 at 13.00 CEST at the Company's main office at Sandakerveien 138, 0484 Oslo, Norway. 

The Company's Nomination and Compensation Committee (NCC) has submitted its formal recommendation to the General Meeting. The recommendation includes proposals for the election of board members, the election of the Chair of the Board, and the remuneration of the Board of Directors and the Nomination Committee.

The recommendation is enclosed with this announcement and is also available on the Company's website: www.lytixbiopharma.com

Following the NCC's recommendation, the Company has received a notice of resignation from Marie Roskrow, Chair of the Board of Directors.

The Board and management wish to express their sincere gratitude to Marie Roskrow for her leadership and dedication over the past two years. During her tenure as Chair, she has played an important role in guiding the company through a critical phase of development and in positioning Lytix for continued success. Her contributions are highly valued and appreciated.

For further information, please contact:

Gjest Breistein, CFO

E-mail: gjest.breistein@lytixbiopharma.com

Phone: +47 952 60 512

About Lytix

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.